aod9604 stimulates adipocyte lipolysis AOD-9604 Before and After: Results AOD-9604 Peptide | USA Made

Description

It is supplied strictly for controlled in-vitro scientific and analytical laboratory research use only by qualified research professionals

Heffernan 2001a Mouse studies using chronic osmotic pump delivery showed AOD-9604 increased fat oxidation and plasma glycerol (a lipolysis marker) to a degree comparable with full-length hGH, without inducing hyperglycaemia or reducing insulin secretion

Scientific Opinion on Dietary Reference Values for cobalamin (vitamin B12)

Since B12 contains cobalt, people with known sensitivities should not receive injections

Commonly Reported Side Effects Mild injection site irritation or redness Headache or fatigue (usually transient in early dosing) Nausea (rare, typically with higher doses or fasted use) In human trials, AOD9604 demonstrated a strong safety profile with no significant adverse effects or changes in glucose, insulin, or organ size. Heffernan et al., Journal of Endocrinology No IGF-1 Elevation or Growth Risks Unlike hGH, AOD9604 does not stimulate systemic growth meaning: No risk of acromegaly or organ hypertrophy No increase in cancer risk tied to IGF-1 elevation No suppression of natural hormone production Not a Controlled Substance AOD9604 is not scheduled or classified as a controlled substance in the U.S